ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.60341
-0.46%
Brent Oil
83.73
0.63%
Bitcoin
66,871.32
2.50%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Adial Pharmaceuticals Inc (ADIL)

  7. Adial Pharmaceuticals Inc (ADIL) Noticias

ADIL

Adial Pharmaceuticals (ADIL)

Adial Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ADIL
FechaHoraFuenteTítuloSímboloCompañía
15/05/202407:30GlobeNewswire Inc.Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ADILAdial Pharmaceuticals Inc
14/05/202416:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ADILAdial Pharmaceuticals Inc
22/04/202407:30GlobeNewswire Inc.Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark OfficeNASDAQ:ADILAdial Pharmaceuticals Inc
10/04/202407:30GlobeNewswire Inc.Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use DisorderNASDAQ:ADILAdial Pharmaceuticals Inc
02/04/202407:30GlobeNewswire Inc.Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business UpdateNASDAQ:ADILAdial Pharmaceuticals Inc
01/03/202418:00GlobeNewswire Inc.Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross ProceedsNASDAQ:ADILAdial Pharmaceuticals Inc
28/02/202408:30GlobeNewswire Inc.Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark OfficeNASDAQ:ADILAdial Pharmaceuticals Inc
14/02/202414:22Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ADILAdial Pharmaceuticals Inc
13/02/202408:15GlobeNewswire Inc.Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark OfficeNASDAQ:ADILAdial Pharmaceuticals Inc
25/01/202415:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ADILAdial Pharmaceuticals Inc
24/01/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ADILAdial Pharmaceuticals Inc
18/01/202415:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADILAdial Pharmaceuticals Inc
18/01/202407:30GlobeNewswire Inc.Adial Announces Appointment of Tony Goodman as Chief Operating OfficerNASDAQ:ADILAdial Pharmaceuticals Inc
12/01/202415:51Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ADILAdial Pharmaceuticals Inc
20/12/202308:00GlobeNewswire Inc.Adial Pharmaceuticals Receives Final Reimbursement Payment from AdovateNASDAQ:ADILAdial Pharmaceuticals Inc
12/12/202315:36Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ADILAdial Pharmaceuticals Inc
08/12/202310:08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ADILAdial Pharmaceuticals Inc
29/11/202315:05GlobeNewswire Inc.Adial Pharmaceuticals Regains Compliance with Nasdaq Listing RequirementNASDAQ:ADILAdial Pharmaceuticals Inc
24/11/202308:24Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ADILAdial Pharmaceuticals Inc
20/11/202306:46Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ADILAdial Pharmaceuticals Inc
14/11/202316:02GlobeNewswire Inc.Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:ADILAdial Pharmaceuticals Inc
08/11/202315:05Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ADILAdial Pharmaceuticals Inc
31/10/202307:30GlobeNewswire Inc.Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine ConferenceNASDAQ:ADILAdial Pharmaceuticals Inc
30/10/202316:24Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:ADILAdial Pharmaceuticals Inc
30/10/202316:18Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ADILAdial Pharmaceuticals Inc
30/10/202316:17Edgar (US Regulatory)Form NT 10-Q/A - Notification of inability to timely file Form 10-Q or 10-QSB: [Amend]NASDAQ:ADILAdial Pharmaceuticals Inc
26/10/202316:20Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ADILAdial Pharmaceuticals Inc
25/10/202307:00GlobeNewswire Inc.Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader WebinarNASDAQ:ADILAdial Pharmaceuticals Inc
24/10/202315:30GlobeNewswire Inc.Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:ADILAdial Pharmaceuticals Inc
20/10/202307:00GlobeNewswire Inc.Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:ADILAdial Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ADIL

Su Consulta Reciente

CCOM
US30
US 30
USOTC
RHHBY
Roche (QX)
USOTC
BNPQY
BNP Paribas (QX)
NYSE
XOM
Exxon Mobil
USOTC
ADDYY
Adidas (QX)
NASDAQ
TSLA
Tesla
NYSE
MRK
Merck
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
BASFY
BASF (QX)
NYSE
AXP
American Express
NYSE
BAC
Bank of America
NYSE
CVX
Chevron
NASDAQ
NVDA
NVIDIA
NYSE
MCD
McDonalds
FX
EURUSD
Euro vs US Dollar
COIN
SOLUSD
Solana
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados